AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Berenberg Bank

Berenberg Bank reissued their buy rating on shares of AstraZeneca (LON:AZN) in a report published on Monday, Marketbeat.com reports. The brokerage currently has a £150 ($197.24) price objective on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on AZN. JPMorgan Chase & Co. reissued an overweight rating on shares of AstraZeneca in a research report on Tuesday, June 4th. Jefferies Financial Group increased their target price on AstraZeneca from GBX 71 ($0.93) to GBX 74 ($0.97) and gave the stock a hold rating in a research report on Tuesday, July 2nd. Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Thursday, July 25th. Citigroup reissued a buy rating on shares of AstraZeneca in a research report on Tuesday, May 28th. Finally, Deutsche Bank Aktiengesellschaft reissued a hold rating and issued a £110 ($144.64) target price on shares of AstraZeneca in a research report on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of £105.53 ($138.77).

AstraZeneca Trading Down 3.9 %

AZN opened at £125.40 ($164.89) on Monday. AstraZeneca has a one year low of GBX 9,461 ($124.40) and a one year high of £133.88 ($176.04). The firm has a market capitalization of £194.37 billion, a price-to-earnings ratio of 4,019.23, a PEG ratio of 1.08 and a beta of 0.15. The business has a 50 day simple moving average of £125.59 and a two-hundred day simple moving average of £117.93. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59.

AstraZeneca Cuts Dividend

The business also recently declared a dividend, which will be paid on Monday, September 9th. Investors of record on Thursday, August 8th will be paid a GBX 77.60 ($1.02) dividend. The ex-dividend date is Thursday, August 8th. This represents a dividend yield of 0.64%. AstraZeneca’s payout ratio is currently 7,500.00%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.